Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow mononuclear cells (Manipal Acunova)
- Development stage
- Unknown
- Lead developer
- Manipal Acunova
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous bone marrow mononuclear cell (BMMC) therapy is a cell-based biologic developed by Manipal Acunova Ltd. for the treatment of ischemic stroke. The therapy involves harvesting a patient's own bone marrow, isolating the mononuclear cell fraction—which includes hematopoietic stem cells, mesenchymal stem cells, and various progenitor cells—and re-administering them to the patient via intravenous infusion. The therapeutic effect is believed to be mediated through paracrine mechanisms, where the cells release trophic factors that reduce apoptosis, dampen peri-infarct inflammation, and promote angiogenesis and neuroprotection. This investigational therapy was evaluated in the Phase 2 InveST (Intravenous Autologous Bone Marrow Mononuclear Cell Therapy for Ischemic Stroke) trial, which assessed safety and efficacy in patients during the subacute phase of stroke (7 to 30 days post-onset).
- Other names
- Autologous BMMCAutologous bone marrow stem cellsBMMC
Beyond the preview
Go deeper on autologous bone marrow mononuclear cells (Manipal Acunova).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow mononuclear cells (Manipal Acunova).